LinkedIn-button

Services

Analytical method development

Our R&D department focuses on developing high quality, stable vaccine products, using state-of-the-art analytical techniques and eight dedicated laboratories. Here, we:

  • develop, improve and validate analytical tests for characterization and quality control of vaccine products,
  • characterize vaccine products, intermediates, seedlots and starting materials,
  • design, develop and improve formulations, delivery systems and adjuvants for vaccines.

State-of-the-art equipment

With state-of-the-art instruments, such as mass spectrometers, NMR, HPLC and GC systems, biosensor and qPCR instruments at their disposal, our experienced staff develop analytical methods for existing and newly developed vaccines. We perform method development, including GMP-compliant method validation, stability studies and consistency in production.

 

Antigen characterization

We have expertise in the field of antigen characterization, i.e. biophysical and immunochemical analysis of vaccines. Our focus is on the primary protein sequences, chemical modifications and higher-order structures and the stability of antigens, and the accessibility of immune-dominant epitopes. The antigens we work with are highly diverse and include purified live attenuated viruses, inactivated viruses, toxoids, outer membrane vesicles, subunit vaccines, conjugated antigens.

 

Test development

In addition, we develop tests to assess the purity and impurities (e.g. host cell proteins and LPS), of a vaccine product, yield, presence of excipients and adjuvants.

 

Strong focus on partnerships

Intravacc has outstanding technical expertise and put a strong focus on our collaboration partners and clients. Flexibility, fast individual response and customer support are a natural part of our daily business.

 

LinkedIn-button

Need more information?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.